In a dismal year for most marijuana stocks, these three winners have bucked the trend.
News & Analysis: Zynerba Pharmaceuticals
Investors appear to be worried about potential safety issues with its cannabinoid gel.
The stock cooled off along with its cannabis-based peers.
The marijuana craze has hit this clinical-stage pharmaceutical company.
These biotech stocks have at least quadrupled in just over six months this year.
Only around 1 in 4 marijuana stocks ended the second quarter higher.
Seven cannabis stocks doubled, and nearly two-thirds of all pot stocks ended the period higher.
A new patent is generating excitement among investors for this clinical-stage biotech stock.
The bottom line: a whole lot of uncertainty.
The biotech received welcome news from the FDA for lead CBD candidate Zygel.